Stryker (SYK) Stock Forecast & Price Target

Stryker
Bull Case

Here are some ways that investors could benefit from investing in Stryker Co.:

• Stryker Co. recently announced a planned leadership succession where Spencer Stiles, the current President and Chief Operating Officer, will succeed Kevin Lobo as Chief Executive Officer effective January 1, 2027, while Lobo transitions to the role of Executive Chair. This internal transition is viewed by analysts as a low-risk move that provides continuity, as Stiles is an established internal leader familiar with the company's operations and strategy, which supports the view that the transition should not materially disrupt execution.
• The stock is currently trading at $276.56, which is near its 52-week low of $267.00, presenting a potential value opportunity as the price has declined significantly from its 52-week high of $392.55. This drop has brought the valuation to a level that some analysts, such as Barclays, have recently upgraded to a "strong-buy" rating, suggesting the stock may be undervalued relative to its long-term growth potential and medical device market position.
• Stryker Co. demonstrated strong financial performance in its most recent earnings report on July 30, 2026, where it reported earnings per share of $3.69, topping the consensus estimate of $3.49 by $0.20. The company also achieved a net margin of 14.43% and a return on equity of 23.63%, with quarterly revenue of $6.59 billion, which was up 9.4% on a year-over-year basis, indicating robust operational efficiency and growth.
• The company maintains a strong dividend profile with a yield of 1.27%, and it is recognized as a Dividend Aristocrat, which appeals to income-focused investors. This consistent dividend payment, combined with the company's stable market position in the healthcare equipment and supplies industry, provides a layer of income stability and capital preservation for long-term holders.
• Stryker Co. has a diversified product portfolio that includes orthopedic implants, surgical equipment, neurovascular devices, and digital and robotic technologies, which reduces reliance on any single product line. This diversification across the MedSurg and Neurotechnology, and Orthopaedics and Spine segments allows the company to capture growth opportunities in various medical specialties and healthcare settings, enhancing its resilience against sector-specific downturns.